Astrazeneca (AZN) said Monday that its drug Imfinzi has been approved by the Food and Drug Administration to treat adult patients with muscle-invasive bladder cancer, in combination with other treatments.
The specific therapy approved is for Imfinzi combined with gemcitabine and cisplatin as a neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy.
The approval for the drug, also called durvalumab, was granted after securing priority review and was based on results from a phase 3 trial in which it showed a 32% reduction in the risk of disease recurrence and a 25% reduction in death risk, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.